Genmab | GEN - Ebitda


Genmab reported DKK401M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Almirall EUR 80.45M 33.61M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.8B 1.25B Sep/2026
argenx SE USD 539M 6M Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bayer EUR 1.62B 529M Sep/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Demant DKK 2.8B 47M Jun/2026
Exelixis USD 275.36M 19.96M Sep/2026
Fresenius Medical Care EUR 817M 26.66M Sep/2026
Genmab DKK 401M 186M Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GN Store Nord DKK 354M 2M Sep/2026
GRIFOLS EUR 505M 32M Sep/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
Insmed USD -80.97M 93.7M Sep/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.68B 82.6M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
UCB EUR 1.6B 570M Dec/2025